2021: Anti-amyloid antibodies take a bumpy road to the clinic

The arrival of the first disease-modifying therapy for Alzheimer’s was significant, but it was not met with the joy that might have been expected.

Michael Eisenstein
1. Michael Eisenstein is a science writer in Philadelphia, Pennsylvania.
View author publications

Search author on: PubMed Google Scholar

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

This article is part of Nature Milestone: Alzheimer’s disease, a supplement produced with financial support from Eisai. Nature maintains full independence in all editorial decisions related to the content. About this content.

Correction 07 November 2024: An earlier version of this article gave the wrong proportions of participants in the lecanemab trial in whom ARIA developed. It also gave the wrong proportions for the number of people showing no disease progression after one year’s treatment with donanemab.

Schenk, D. et al. Nature 400, 173–177 (1999).
Article PubMed Google Scholar
Gilman, S. et al. Neurology 64, 1553–1562 (2005).
Article PubMed Google Scholar
Bard, F. et al. Nature Med. 6, 916–919 (2000).
Article PubMed Google Scholar
Salloway, S. et al. Neurology 73, 2061–2070 (2009).
Article PubMed Google Scholar
Vandenberghe, R. et al. Alz. Res. Ther. 8, 18 (2016).
Article Google Scholar
Salloway, S. et al. N. Engl. J. Med. 370, 322–333 (2014).
Article PubMed Google Scholar
Budd Haeberlein, S. et al. J. Prev. Alz. Dis. 9, 197–210 (2022).
Article Google Scholar
van Dyck, C. H. et al. N. Engl. J. Med. 388, 9–21 (2023).
Article PubMed Google Scholar
Sims, J. R. et al. JAMA 330, 512–527 (2023).
Article PubMed Google Scholar